Decoy Appoints New Chair of Scientific Advisory Board
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: PRnewswire
- Enhanced Scientific Leadership: Decoy Therapeutics has appointed Dr. Brad L. Pentelute, a Professor at MIT, as Chair of its Scientific Advisory Board, aiming to advance the clinical development of its Designable Multi-Antivirals (D-MAVs™) and strengthen its competitive position in the antiviral sector.
- Innovation-Driven Technology: Dr. Pentelute's research focuses on rapid flow peptide synthesis and intracellular delivery, which, combined with Decoy's IMP3ACT™ platform, is expected to significantly shorten development timelines and enhance market responsiveness for drug candidates.
- Strategic Direction Guidance: As Chair of the SAB, Dr. Pentelute will leverage his extensive knowledge in peptide therapeutics to guide Decoy's scientific direction, helping the company pioneer new pathways in multi-viral targeting therapies and drive innovation in antiviral drug development.
- Positive Outlook Ahead: Decoy's D-MAVs™ aim to disrupt the traditional one-virus, one-drug model by designing across shared viral mechanisms, which is anticipated to bring revolutionary changes to global antiviral treatment and meet the increasing public health demands.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DCOY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DCOY
About DCOY
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Decoy Appoints New Chair of Scientific Advisory Board
- Enhanced Scientific Leadership: Decoy Therapeutics has appointed Dr. Brad L. Pentelute, a Professor at MIT, as Chair of its Scientific Advisory Board, aiming to advance the clinical development of its Designable Multi-Antivirals (D-MAVs™) and strengthen its competitive position in the antiviral sector.
- Innovation-Driven Technology: Dr. Pentelute's research focuses on rapid flow peptide synthesis and intracellular delivery, which, combined with Decoy's IMP3ACT™ platform, is expected to significantly shorten development timelines and enhance market responsiveness for drug candidates.
- Strategic Direction Guidance: As Chair of the SAB, Dr. Pentelute will leverage his extensive knowledge in peptide therapeutics to guide Decoy's scientific direction, helping the company pioneer new pathways in multi-viral targeting therapies and drive innovation in antiviral drug development.
- Positive Outlook Ahead: Decoy's D-MAVs™ aim to disrupt the traditional one-virus, one-drug model by designing across shared viral mechanisms, which is anticipated to bring revolutionary changes to global antiviral treatment and meet the increasing public health demands.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Decoy Therapeutics Showcases Novel Antiviral Therapies in Boston
- Leadership Roundtable: Chief Business Officer Peter Marschel will lead a 60-minute roundtable at the Oligonucleotide & Peptides HubXchange on April 30, discussing key challenges in computational design of peptide therapeutics, aiming to drive innovation in peptide drug design and enhance the company's competitiveness in the antiviral space.
- New Strategic Partnership: Decoy has formed a strategic partnership with Quantorito to deploy a Google Cloud-native, AI-driven peptide design platform, significantly shortening the cycle from peptide design to D-MAV candidates, showcasing how computational work can accelerate the shift from ligand reengineering to de novo design, further advancing the company's technological progress.
- Case Study Presentation: Chief Scientific Officer Barbara Hibner and Chief Technology Officer Michael Lipp will co-present a case study on
See More
Decoy Therapeutics Launches Multi-Virus Antiviral Platform
- Platform Innovation: Decoy Therapeutics' IMP³ACT™ platform dramatically compresses drug development timelines from years to months through AI-driven design and rapid synthesis, positioning the company for swift clinical entry and significant competitive advantage in the antiviral market.
- Multi-Virus Targeting: The D-MAV antiviral candidate DCOY-COV is designed for high-risk populations and has demonstrated broad in vitro activity against multiple human coronaviruses, with a Phase 1 clinical trial expected in 2027, potentially unlocking substantial market opportunities for the company.
- Market Potential: The DCOY-TRI program aims to target influenza, coronaviruses, and paramyxoviruses with a single D-MAV, potentially addressing 55-70% of viruses causing respiratory infections annually, thereby solidifying Decoy's position in the global antiviral market.
- Strategic Development: Decoy is entering a catalytic phase, planning to accelerate clinical proof-of-concept through human challenge studies, aligning with the growing global demand for broad-spectrum antiviral solutions, enhancing investor confidence, and driving long-term growth for the company.
See More
Decoy Therapeutics Launches Multi-Viral Antiviral Platform
- Strategic Partnerships Enhance Capabilities: Decoy Therapeutics has formed a strategic alliance with Quantori and Google Cloud, expected to increase computational peptide design capacity by 25-100 times, thereby accelerating candidate drug discovery and optimization, enhancing the company's competitiveness in the antiviral market.
- Global Recognition and Commitment: The company has been recognized as a Hello Tomorrow Deep Tech Pioneer, highlighting its breakthrough technology, while also establishing a Global Access Commitment with the Gates Foundation to support low-cost manufacturing and global distribution of antiviral therapies, thereby enhancing brand visibility.
- Innovative Platform Accelerates R&D: Decoy's IMP³ACT™ platform integrates AI-driven design and rapid synthesis, significantly compressing drug development timelines from years to months, facilitating the rapid advancement of multiple pipeline programs to meet global demand for broad-spectrum antiviral solutions.
- Clinical Trials and Market Potential: The company plans to initiate a Phase 1 clinical trial for DCOY-COV in 2027, targeting high-risk populations, while its multi-virus respiratory program DCOY-TRI could potentially address 55-70% of viruses causing respiratory infections annually, indicating substantial market potential.
See More
Decoy Therapeutics CEO to Participate in Investor Event
- Investor Event Scheduled: Decoy Therapeutics CEO Rick Pierce will participate in a virtual Investor Closing Bell event on April 9, 2026, at 4:00 PM ET, where he will provide a corporate overview and business outlook, aimed at enhancing investor confidence in the company's future development.
- Interactive Q&A Session: During the event, investors and interested parties will have the opportunity to submit questions live, with Decoy aiming to answer as many as possible within the time allowed, reflecting the company's commitment to transparency and investor relations, which may increase market interest in its novel antiviral drugs.
- Technology Platform Overview: Decoy's IMP³ACT platform integrates AI-enabled design and rapid synthesis to expedite the clinical progression of antiviral drugs, particularly candidates targeting multiple respiratory viruses, showcasing the company's innovative potential in viral prevention and treatment.
- Forward-Looking Statements: The press release includes forward-looking statements that highlight future development goals and potential risks, urging investors to consider various factors that could impact the company's performance, ensuring a comprehensive understanding for investment decisions.
See More
Decoy Appoints New Chair of Scientific Advisory Board
- Enhanced Scientific Leadership: Decoy Therapeutics has appointed Dr. Brad L. Pentelute, a Professor at MIT, as Chair of its Scientific Advisory Board, aiming to advance the clinical development of its Designable Multi-Antivirals (D-MAVs™) and strengthen its competitive position in the antiviral sector.
- Innovation-Driven Technology: Dr. Pentelute's research focuses on rapid flow peptide synthesis and intracellular delivery, which, combined with Decoy's IMP3ACT™ platform, is expected to significantly shorten development timelines and enhance market responsiveness for drug candidates.
- Strategic Direction Guidance: As Chair of the SAB, Dr. Pentelute will leverage his extensive knowledge in peptide therapeutics to guide Decoy's scientific direction, helping the company pioneer new pathways in multi-viral targeting therapies and drive innovation in antiviral drug development.
- Positive Outlook Ahead: Decoy's D-MAVs™ aim to disrupt the traditional one-virus, one-drug model by designing across shared viral mechanisms, which is anticipated to bring revolutionary changes to global antiviral treatment and meet the increasing public health demands.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Decoy Therapeutics Showcases Novel Antiviral Therapies in Boston
- Leadership Roundtable: Chief Business Officer Peter Marschel will lead a 60-minute roundtable at the Oligonucleotide & Peptides HubXchange on April 30, discussing key challenges in computational design of peptide therapeutics, aiming to drive innovation in peptide drug design and enhance the company's competitiveness in the antiviral space.
- New Strategic Partnership: Decoy has formed a strategic partnership with Quantorito to deploy a Google Cloud-native, AI-driven peptide design platform, significantly shortening the cycle from peptide design to D-MAV candidates, showcasing how computational work can accelerate the shift from ligand reengineering to de novo design, further advancing the company's technological progress.
- Case Study Presentation: Chief Scientific Officer Barbara Hibner and Chief Technology Officer Michael Lipp will co-present a case study on
See More
Decoy Therapeutics Launches Multi-Virus Antiviral Platform
- Platform Innovation: Decoy Therapeutics' IMP³ACT™ platform dramatically compresses drug development timelines from years to months through AI-driven design and rapid synthesis, positioning the company for swift clinical entry and significant competitive advantage in the antiviral market.
- Multi-Virus Targeting: The D-MAV antiviral candidate DCOY-COV is designed for high-risk populations and has demonstrated broad in vitro activity against multiple human coronaviruses, with a Phase 1 clinical trial expected in 2027, potentially unlocking substantial market opportunities for the company.
- Market Potential: The DCOY-TRI program aims to target influenza, coronaviruses, and paramyxoviruses with a single D-MAV, potentially addressing 55-70% of viruses causing respiratory infections annually, thereby solidifying Decoy's position in the global antiviral market.
- Strategic Development: Decoy is entering a catalytic phase, planning to accelerate clinical proof-of-concept through human challenge studies, aligning with the growing global demand for broad-spectrum antiviral solutions, enhancing investor confidence, and driving long-term growth for the company.
See More
Decoy Therapeutics Launches Multi-Viral Antiviral Platform
- Strategic Partnerships Enhance Capabilities: Decoy Therapeutics has formed a strategic alliance with Quantori and Google Cloud, expected to increase computational peptide design capacity by 25-100 times, thereby accelerating candidate drug discovery and optimization, enhancing the company's competitiveness in the antiviral market.
- Global Recognition and Commitment: The company has been recognized as a Hello Tomorrow Deep Tech Pioneer, highlighting its breakthrough technology, while also establishing a Global Access Commitment with the Gates Foundation to support low-cost manufacturing and global distribution of antiviral therapies, thereby enhancing brand visibility.
- Innovative Platform Accelerates R&D: Decoy's IMP³ACT™ platform integrates AI-driven design and rapid synthesis, significantly compressing drug development timelines from years to months, facilitating the rapid advancement of multiple pipeline programs to meet global demand for broad-spectrum antiviral solutions.
- Clinical Trials and Market Potential: The company plans to initiate a Phase 1 clinical trial for DCOY-COV in 2027, targeting high-risk populations, while its multi-virus respiratory program DCOY-TRI could potentially address 55-70% of viruses causing respiratory infections annually, indicating substantial market potential.
See More
Decoy Therapeutics CEO to Participate in Investor Event
- Investor Event Scheduled: Decoy Therapeutics CEO Rick Pierce will participate in a virtual Investor Closing Bell event on April 9, 2026, at 4:00 PM ET, where he will provide a corporate overview and business outlook, aimed at enhancing investor confidence in the company's future development.
- Interactive Q&A Session: During the event, investors and interested parties will have the opportunity to submit questions live, with Decoy aiming to answer as many as possible within the time allowed, reflecting the company's commitment to transparency and investor relations, which may increase market interest in its novel antiviral drugs.
- Technology Platform Overview: Decoy's IMP³ACT platform integrates AI-enabled design and rapid synthesis to expedite the clinical progression of antiviral drugs, particularly candidates targeting multiple respiratory viruses, showcasing the company's innovative potential in viral prevention and treatment.
- Forward-Looking Statements: The press release includes forward-looking statements that highlight future development goals and potential risks, urging investors to consider various factors that could impact the company's performance, ensuring a comprehensive understanding for investment decisions.
See More
